Harmful Medicines-Trasylol, Prempro
Know The Facts Before Filing A Trasylol Lawsuit
In taking drugs or any medical practices, you need to be assured that there is a high possibility and a very small standard error when it comes to its effectiveness. What we are dealing here is life that is why we really have to be careful. Because of this, we are choosing medical companies whom we have assured us this confidence. But what would you do if your trusted company has offered you drugs or medical practices, though effective will give you another risk for side effects. Lawsuits will surely come in their way.
Trasylol lawsuits have been filed and being talked about around United States claiming that the heart surgery drug is an ineffective prescription. They allege that Trasylol (aprotinin) has caused kidney failure, heart attacks and strokes. These aprotinin lawsuits accused Bayer, the drug’s producer, advertized and sold Trasylol as a harmless and effective medication to aid in the prevention of excessive bleeding during bypass surgery. They also claim that Bayer did not do their task to warn the patiens of the possible side effects of aprotinin.
Bayer argues that the extensive study of aprotinin shows increased chance of serious problems and death in Trasylol takers. The contributory relationship between Trasylol and these likely incurable side effects has been known formany years and there is supporting evidence that Bayer has known about his connection between Trasylol and kidney failure even before 1980’s. Dr. Juergen Fischer, a German scientist who is the chairperson of the Institute of Experimental Medicine at the University of Cologne, discovered stern cases of kidney damage in animals that were given Trasylol more than 20 years ago. According to Dr. Fischer, he was shocked that Bayer is not interested in these findings.
On the other hand, lawsuits are still filed in the Supreme Court of the United States on behalf of the patients who suffered from kidney failure and stroke problems and from families who are fighting for the unlawful deaths of their loved ones who died after their heart surgeries. The justices are scheduled to examine another lawsuit in the case of Wyeth. This case is about the question of whether a patient who has been affected by a drug can file a case under state law if the drug was approved by FDA. The possible consequence of this decision cannot be taken for granted. Patients damaged by ineffective medicines, including those who filed a Trasylol lawsuit, will be affected by the Supreme Court’s verdict on this case.
The Wyeth case concerns Diana Levine, a Vermont guitarist, who was injected with Phenergan, a drug for nausea, and consequently developed gangrene that led to the amputation of her arm. She took legal action against the drug’s manufacturer, Wyeth, complaining that the company did not warn their consumers sufficiently of the possible effects of the injections. The NEJM editors and scores of others concerned with patients’ safety are anxious about the rights of patients that are eroded in the face of preemption opinions intended to defend drug manufacturers. Proponents of preemption stand in the position that the FDA examines the risks and benefits of a drug’s safety and after approval the drug company should be confined from lawsuits by patients who were harmed by the approved drug.
